Amgen shares pare losses as drugmaker sees no bone safety concerns in obesity drug
CEO Bob Bradway said Amgen is "well advanced" in preparing to launch a Phase 3 testing round of MariTide in order to have enough data to allow the drug to receive approval from regulators. Amgen has also begun to examine a different weight-loss drug candidate, although few details have been disclosed, Reuters reported.
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...
according to Amgen. The drug was given as a subcutaneous injection every four weeks in the study, and showed a clear dose response with a 7.2% weight loss in the lowest dose group (140 mg ...
A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...
Amgen stock soared as much as 16% on Friday after it reported first-quarter earnings. The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug ...
Investors are still waiting for Amgen's new weight loss drug, MariTide (formerly AMG133), its injectable obesity drug. MariTide's early stage testing showed an average of 14.5% weight ...
“A successful obesity drug could move growth into double-digit territory,” says Morningstar analyst Karen Andersen. Amgen shares offer investors a cheaper way to play the weight-loss ...
The drug will still likely have the intestinal side effects common to GLP-1 drugs, but those symptoms may be more manageable with less frequent treatments. Amgen's success in the weight loss ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback